|
|
||||||||
1From the Beijing Institute of Ophthalmology and the 3Department of Ophthalmology, Beijing TongRen Eye Center, Capital University of Medical Sciences, Beijing, China; and the 2Department of Immunology, General Hospital of PLA, Beijing, China.
| Abstract |
|---|
|
|
|---|
METHODS. A rat model of penetrating keratoplasty, whereby Fisher344 donor corneas are implanted into Lewis recipients, was used to evaluate the effects of SEB on inhibiting immune-mediated allograft rejection. To induce anergy, SEB was injected into the peribulbar space of Lewis rats. Furthermore, histopathology and immunofluorescent staining were used to examine the levels of infiltrating CD4+ and CD8+ T lymphocytes and NK1.1+ lymphocytes.
RESULTS. By administering SEB, at doses of 90 or 120 µg/kg 7 days before and after keratoplasty, we suppressed the episode of corneal graft rejection for a median of 12 and 30 days, respectively. In contrast, rejection was observed when 30 or 60 µg/kg of SEB was administered. After SEB injections, lymphocyte infiltration into the corneal grafts was reduced, and the expression of NK1.1+ lymphocytes was enhanced, suggesting that anergy may be occurring. Also, there were no differences in the number of infiltrating CD4+ and CD8+ T lymphocytes cells between the control group and groups injected with 30 and 120 µg/kg SEB on postoperative days 10 and 30.
CONCLUSIONS. Inducing anergy with the superantigen SEB prolonged corneal graft survival in a rat model of penetrating keratoplasty. Therefore, these results support the possibility of prolonging corneal allograft survival in a clinical setting by preventing immune-mediated rejection through the administration of the superantigen SEB.
The term superantigen (SAg) is used to describe those microbial products that activate a large portion of the T-cell population (5%30%), whereas conventional antigens stimulate only 0.01%. Superantigens differ from conventional antigens in that they bind to the outside of the peptide-binding groove of MHC class, thus exerting their effects as an intact molecule without being processed. Furthermore, recognition of SAgs by the T-cell receptor (TCR) depends only on the variable region of the TCR ß chain (Vß). Therefore, SAgs stimulate both antigen-presenting cells (APCs) and T lymphocytes, which leads to the massive production of cytokines, enhanced expression and/or activation of cell adhesion molecules, T-cell proliferation, activation-induced apoptosis, and T-cell anergy.4 A study has shown that injecting the SAg staphylococcal enterotoxin B (SEB) into mice produces transient, rapid hyperactivation and proliferation of T cells, which are eliminated by activation-induced cell death within 48 hours.5 In addition, the remaining SAg-reactive cells fail to proliferate in response to a secondary SAg challenge. The proliferative unresponsiveness of the secondary SAg responder T cells has been termed anergy. However, on subsequent analysis, secondary SAg responder T cells may not be truly anergic because they could be reacting to the second SAg exposure.6 Wang et al.7 showed that CD8+ regulatory suppressive T cells could enforce anergy by inhibiting cell division of preactivated T cells, not by the SAg response of naïve T cells.
Damage to healthy, transplanted tissue can be curtailed by reducing the inflammatory response of the immune system. Our studies have shown that the bacterial superantigen SEB can inhibit the rejection of transplanted mouse bone marrow cells and peripheral lymphocytes, suggesting that injections of SEB may induce peripheral anergy to allogeneic organ grafts. In addition, CD4+ T cells appear responsible for maintaining this anergy rather than the CD8+ T cells.8 Our studies confirmed that the induction of transplantation anergy by SEB injections contribute to hematopoietic chimerism, defined as the coexistence of host and donor cells, and that mixed lymphocyte reactions (MLRs) are significantly low. This in vivo SEB-induced anergy may be associated with the clone deletion of T-helper (Th)1 cells. The specific dosage of SEB is critical because, if the dosage is too high or too low, then anergy may not develop in the injected mice.8 9
Several mechanisms that can induce CD4+ T-cell death or unresponsiveness have been identified. These mechanisms include T-cell anergy, which is due to the absence of costimulation at the time of activation, and Fas-mediated activation-induced cell death (AICD). Cytokines, such as IFN-
, TNF-
, and IL-10, can also mediate T-cell suppression; however, the detailed mechanisms involved in the induction of these cytokine-regulated T-cell death pathways have not been fully characterized.10
Bacterial SAgs are a large group of polypeptides that are produced by bacterial strains, such as Staphylococcus aureus and S. pyrogenes. SAgs have been implicated in the pathogenesis of toxic-shocklike syndromes in both animal models and in humans. In particular, the in vivo immune response to the S. aureus SAg SEB represents a useful model for studying in vivo cytokine regulation and the phenomenon of peripheral T-cell unresponsiveness. After their initial clonal expansion and cytokine production, SEB-reactive T cells are thought to become unresponsive to further TCR stimulation.11 T-cell deletion and unresponsiveness could be induced by oral administration or intrathymic injection of low doses of SEB, which could result in not only gut-associated lymphoid tissue (GALT) and thymic alterations but also peripheral pivotal immune alterations.12 13
The SEB used in this study was produced from S-6 cocci ferment, which has a molecular mass of 2.84 to 2.9 kDa and an isoelectric point of 8.6, and purified by affinity chromatography. In our previous experiments, SEB selectively decreased the percent of CD4+ T cells and CD4+ T/H2Kb cells, but had no effect on the number of CD8+ cells after allogenic mouse cell transplantation. Accordingly, the proliferative response caused by MLRs in the recipient mouse decreased significantly.8 Herein, we report that treating an inbred rat model of allograft keratoplasty rejection with SEB injections into the peribulbar space at preoperative and postoperative day 7 led to rat immune unresponsiveness (anergy), which persisted for 15 to 20 days after only one injection. Because SEB entered the blood and induced CD4+ and CD8+ T lymphocyte unresponsiveness, it appears that the effect was systemic.8 In all, we used the superantigen SEB to induce anergy for the purpose of prolonging corneal allograft survival and to observe any subsequent immune reactions.
| Materials and Methods |
|---|
|
|
|---|
Induction of Anergy
The SAg, staphylococcal enterotoxin B (SEB; Chinese Patent No. 01103991.4) was used for inducing anergy. SEB, at doses of 30, 60, 90, or 120 µg/kg were injected into the peribulbar space of each Lew inbred rat 7 days before and after keratoplasty. Thirty-six Lew rats were divided into six groups as follows: group 1 F344/Lew (control, 0.2 mL saline buffer, peribulbar); group 2 F344/Lew (SEB, 30 µg/kg body weight, peribulbar); group 3 F344/Lew (SEB, 60 µg/kg body weight, peribulbar); group 4 F344/Lew (SEB, 90 µg/kg body weight, peribulbar); group 5 F344/Lew (SEB, 120 µg/kg body weight, peribulbar); and group 6 Lew/Lew (no treatment).
Orthotropic Corneal Transplantation
F344 corneal grafts (3 mm diameter) were transplanted orthotopically into anesthetized Lew eyes by a procedure described by Ma et al.3 Both the donor graft and the recipient graft bed were scored with 3- and 2.5-mm trephines. The donor graft was sewn into place with eight interrupted 10-0 nylon (Alcon Laboratories, Fort Worth, TX) sutures. To protect the transplant, a blepharorrhaphy was attached by means of two interrupted sutures and remained in place for 1 day. Also, 2 mg of tobramycin and 0.2 mg of dexamethasone were subconjunctival injected immediately after surgery and for 3 days after surgery.
Assessment of Graft Survival
After surgery, all rats were subjected to clinical examinations by slit lamp microscopy every day for 2 weeks followed by twice a week thereafter. The transplants were evaluated using a modified form of a previously described scoring system. The scoring system took into account opacity, edema, and neovascularization14 (Table 1) . An immune-mediated rejection episode was considered to occur if the combined score of all three factors were equal to or exceeded 6. Also, the mean survival time for each group was calculated.
|
Statistical Analysis
The mean survival time (MST) and the clinical scoring data were compared between the various groups by means of one-way ANOVA and the independent-sample t-test, on computer (SPSS for Windows, ver. 10.0; SPSS Science, Chicago, IL).
| Results |
|---|
|
|
|---|
On postoperative day 10, all grafts from groups 1 to 3 exhibited rejection episodes (Figs. 1A 1B 1C) . The grafts exhibited severe edema and infiltration into the epithelium and stroma, and newly formed vessels began to penetrate the transplanted grafts. However, in groups 4 and 5, almost all grafts showed no indications of rejection and no alteration in their normal, physiological transparency (Figs. 1D 1E) . Accordingly, isografts from group 6 showed no immunologic reaction (Fig. 1F) . On postoperative day 30, all grafts from groups 1 to 3 exhibited scarring (Figs. 2A 2B 2C , respectively), several grafts from groups 4 and 5 exhibited no immune-mediated rejection (Figs. 2D 2E) , and all grafts from group 6 remained transparent (Fig. 2F) .
|
|
|
|
|
Immunofluorescent staining for rat CD4+ and CD8+ T cells, using the monoclonal antibodies OX35 and OX8, respectively, revealed that there were no differences in the amount of infiltrating CD4+ and CD8+ T lymphocytes between all groups at postoperative days 10 and 30 (data not shown).
However, immunofluorescent staining for NK1.1+ lymphocytes, using the monoclonal antibody R-PE-conjugated mouse anti-rat CD161a (NKR-P1A) showed significant differences in the rat corneal epithelium and central stroma of the control group and the 120 µg/kg SEBinjected group on postoperative days 10 and 30 (Fig. 5) .
|
| Discussion |
|---|
|
|
|---|
The mechanism of tolerance induced by SEB is poorly understood. Immunity studies have shown that peripheral deletion in response to soluble Ag is one mechanism by which the immune system eliminates self-reactive T cells that escape thymic deletion. Experimental models, in which SAgs are injected into normal mice or relevant peptide Ags are injected into TCR transgenic mice, have provided evidence for peripheral deletion.21 Another potential mechanism for silencing T cells is functional inactivation, often referred to as anergy. Based largely on in vitro experiments with Th1 clones, anergy is defined as a defect in TCR-dependent proliferation that is acquired as a result of prior TCR stimulation in the absence of APC-derived costimulatory signals or proliferation.22
Our study evaluated the potential use of SEB as a strategy for preventing corneal graft rejection. The SEB used in our experiment prolonged rat graft survival by reducing lymphocyte infiltration, edema, and neovascularization. Because graft rejection is typically due to corneal infiltration, we used corneal opacity as a marker of immune-mediated rejection. The data in Figure 3B show that the scores of corneal opacity in groups 4 and 5 were equal to or below group two and less than groups 1 and 3. Because the number of rats in each group were different (especially group 3) and because dexamethasone was used in our experiments during the first three postoperative days, more experiments should be performed to verify that SEB plays a role in avoiding corneal allograft rejection through the induction of anergy.
Also, the infiltration of inflammatory lymphocytes into grafts in group 5 (treated by SEB 120 µg/kg, peribulbar) was reduced. The expression of CD4+ and CD8+ T cells was unchanged after SEB injection in all rat corneal grafts; however, there were more NK1.1+ lymphocytes present in the corneal grafts from group 5 (120 µg/kg SEB) than in control grafts. These results suggest that T cells were unresponsive,23 but the absence of an immune response must be confirmed. In addition, more work is needed to help explain further the unchanged expression of CD4+ and CD8+ T cells and the increased expression of NK1.1 T cells in the rat corneal grafts.
In summary, these findings suggest the feasibility of using SEB-induced anergy as a means of reducing corneal allograft rejection. Whether administration of SEB can enhance allograft tolerance and permit the use of a less-intensive postoperative treatment for patients should be verified further. The remarkable capacity of SEB to prevent rejection in an otherwise high-risk setting suggests that SEB may be useful as a treatment in high-risk keratoplasty in humans; however, well-controlled clinical trials are needed to confirm this assertion.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication August 20, 2002; revised February 25 and March 18, 2003; accepted March 27, 2003.
Disclosure: Z. Pan, None; Y. Chen, None; W. Zhang, None; Y. Jie, None; N. Li, None; Y. Wu, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Zhiqiang Pan, Beijing Institute of Ophthalmology, Beijing TongRen Eye Center, Capital University of Medical Sciences, 17# Hou Gou Lane, ChongNei Street, Beijing 100730, China; ebank416{at}msn.com.
| References |
|---|
|
|
|---|
J Immunol 165,6056-6066This article has been cited by other articles:
![]() |
Y Jie, Z Pan, Y Chen, Y Wei, W Zhang, Y Wu, H Peng, and L Xu Non-specific tolerance induced by staphylococcal enterotoxin B in treating high risk corneal transplantation in rats Br. J. Ophthalmol., March 1, 2005; 89(3): 364 - 368. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |